KRAS and colorectal carcinoma: Having shown that PRMT5 inhibition leads to a further decrease in cell viability in the KRAS mutant CRC cells when compared to the KRAS WT CRC cells, we next sought to determine whether the KRAS mutant CRC cells would show a greater level of apoptosis after 60 h of 10 μM PRMT5 inhibitor treatment when compared to the KRAS WT CRC cells.